Adcetris Infusion
Brentuximab vedotin
50mg
TAKEDA PHARMA A/S
| Pack size | 1 Glass Vial |
|---|---|
| Dispensing mode | POM |
| Source | DENMARK |
| Agent | Modern Pharmaceutical Co. |
| Retail Price | 19181.50 AED |
Indications
Adcetris Infusion is used for:
Used in the treatment of Hodgkin lymphoma and systemic anaplastic large cell lymphoma.
Adult Dose
Child Dose
Renal Dose
Administration
Contra Indications
Precautions
Pregnancy-Lactation
Interactions
Adverse Effects
Side effects of Brentuximab vedotin :
Mechanism of Action
Brentuximab vedotin is composed of 3 parts: a chimeric human-murine IgG1 that targets CD30, monomethyl auristatin E (MMAE),which is a microtubule disrupting agent, and a protease-susceptible linker that covalently links the antibody and MMAE. The IgG1 antibody enables brentuximab vedotin to target tumor cells expressing CD30 on their cell surface then brentuximab vedotin gets internalized into the cell. Once inside, the linker is cleaved releasing MMAE which binds disrupts the microtuble network.
Note
Adcetris 50mg Infusion manufactured by TAKEDA PHARMA A/S. Its generic name is Brentuximab vedotin. Adcetris is availble in United Arab Emirates.
Farmaco UAE drug index information on Adcetris Infusion is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.